Epclusa® (sofosbuvir/velpatasvir) – Expanded indication
August 1, 2017 – Gilead announced the FDA approval of Epclusa (sofosbuvir/velpatasvir) tablets, to include use in patients co-infected with the hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1).
Download PDF
